New radioimmunoconjugate -dota-h-r3. synthesis and radiolabeling

Abstract

Labelling of monoclonal antibodies with radioactive metals for cancer diagnosis and therapy has usually been accomplished by the use of bifunctional chelating agents, which contain both a reactive functionality for covalent attachment to proteins and a strong metal-binding group capable of forming a physiologically stable complex with the radionuclide. The objective of the present work was to modify the humanized monoclonal antibody (h-R3) with the 1,4,7,10-tetraaza-cyclododecane N,N´,N´´,N´´´-tetraacetic acid (DOTA) in aqueous solution, achieve the labelling of the obtained conjugates with and study some of the variables that influence in the labelling reaction, as well as the stability of the radioimmunoconjugate in presence of other chelating agents.